Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 125

1.

Development of an Fn14 agonistic antibody as an anti-tumor agent.

Michaelson JS, Amatucci A, Kelly R, Su L, Garber E, Day ES, Berquist L, Cho S, Li Y, Parr M, Wille L, Schneider P, Wortham K, Burkly LC, Hsu YM, Joseph IB.

MAbs. 2011 Jul-Aug;3(4):362-75. Epub 2011 Jul 1.

PMID:
21697654
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

The anti-Fn14 antibody BIIB036 inhibits tumor growth in xenografts and patient derived primary tumor models and enhances efficacy of chemotherapeutic agents in multiple xenograft models.

Michaelson JS, Kelly R, Yang L, Zhang X, Wortham K, Joseph IB.

Cancer Biol Ther. 2012 Jul;13(9):812-21. Epub 2012 Jun 6.

PMID:
22669574
[PubMed - indexed for MEDLINE]
3.

TWEAK signals through JAK-STAT to induce tumor cell apoptosis.

Chapman MS, Wu L, Amatucci A, Ho SN, Michaelson JS.

Cytokine. 2013 Jan;61(1):210-7. doi: 10.1016/j.cyto.2012.09.020. Epub 2012 Oct 27.

PMID:
23107828
[PubMed - indexed for MEDLINE]
4.

Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.

Salzmann S, Seher A, Trebing J, Weisenberger D, Rosenthal A, Siegmund D, Wajant H.

J Biol Chem. 2013 May 10;288(19):13455-66. doi: 10.1074/jbc.M112.435917. Epub 2013 Mar 26.

PMID:
23532848
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells.

Zhou H, Marks JW, Hittelman WN, Yagita H, Cheung LH, Rosenblum MG, Winkles JA.

Mol Cancer Ther. 2011 Jul;10(7):1276-88. doi: 10.1158/1535-7163.MCT-11-0161. Epub 2011 May 17.

PMID:
21586630
[PubMed - indexed for MEDLINE]
Free PMC Article
6.

Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death.

Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H.

J Immunol. 2003 Jan 1;170(1):341-8.

PMID:
12496418
[PubMed - indexed for MEDLINE]
Free Article
7.

Fn14•TRAIL effectively inhibits hepatocellular carcinoma growth.

Aronin A, Amsili S, Prigozhina TB, Tzdaka K, Rachmilewitz J, Shani N, Tykocinski ML, Dranitzki Elhalel M.

PLoS One. 2013 Oct 10;8(10):e77050. doi: 10.1371/journal.pone.0077050. eCollection 2013.

PMID:
24130833
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

RG7212 anti-TWEAK mAb inhibits tumor growth through inhibition of tumor cell proliferation and survival signaling and by enhancing the host antitumor immune response.

Yin X, Luistro L, Zhong H, Smith M, Nevins T, Schostack K, Hilton H, Lin TA, Truitt T, Biondi D, Wang X, Packman K, Rosinski J, Berkofsky-Fessler W, Tang JP, Pant S, Geho D, Vega-Harring S, Demario M, Levitsky H, Simcox M.

Clin Cancer Res. 2013 Oct 15;19(20):5686-98. doi: 10.1158/1078-0432.CCR-13-0405. Epub 2013 Aug 23.

PMID:
23974006
[PubMed - indexed for MEDLINE]
Free Article
9.

Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14).

Fick A, Lang I, Schäfer V, Seher A, Trebing J, Weisenberger D, Wajant H.

J Biol Chem. 2012 Jan 2;287(1):484-95. doi: 10.1074/jbc.M111.287656. Epub 2011 Nov 11.

PMID:
22081603
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment.

Zhou H, Ekmekcioglu S, Marks JW, Mohamedali KA, Asrani K, Phillips KK, Brown SA, Cheng E, Weiss MB, Hittelman WN, Tran NL, Yagita H, Winkles JA, Rosenblum MG.

J Invest Dermatol. 2013 Apr;133(4):1052-62. doi: 10.1038/jid.2012.402. Epub 2012 Nov 29.

PMID:
23190886
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Antitumor activity of a humanized, bivalent immunotoxin targeting fn14-positive solid tumors.

Zhou H, Hittelman WN, Yagita H, Cheung LH, Martin SS, Winkles JA, Rosenblum MG.

Cancer Res. 2013 Jul 15;73(14):4439-50. doi: 10.1158/0008-5472.CAN-13-0187. Epub 2013 May 30.

PMID:
23722548
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

The cytokine tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 have a neuroprotective effect in the central nervous system.

Echeverry R, Wu F, Haile WB, Wu J, Yepes M.

J Neuroinflammation. 2012 Mar 6;9:45. doi: 10.1186/1742-2094-9-45.

PMID:
22394384
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

TWEAK/Fn14 pathway: a nonredundant role in intestinal damage in mice through a TWEAK/intestinal epithelial cell axis.

Dohi T, Borodovsky A, Wu P, Shearstone JR, Kawashima R, Runkel L, Rajman L, Dong X, Scott ML, Michaelson JS, Jakubowski A, Burkly LC.

Gastroenterology. 2009 Mar;136(3):912-23. doi: 10.1053/j.gastro.2008.11.017. Epub 2008 Nov 8.

PMID:
19109961
[PubMed - indexed for MEDLINE]
14.

Therapeutic targeting of TWEAK/Fnl4 in cancer: exploiting the intrinsic tumor cell killing capacity of the pathway.

Michaelson JS, Burkly LC.

Results Probl Cell Differ. 2009;49:145-60. doi: 10.1007/400_2008_18. Review.

PMID:
19513634
[PubMed - indexed for MEDLINE]
15.

The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression.

Tran NL, McDonough WS, Savitch BA, Sawyer TF, Winkles JA, Berens ME.

J Biol Chem. 2005 Feb 4;280(5):3483-92. Epub 2004 Dec 16.

PMID:
15611130
[PubMed - indexed for MEDLINE]
Free Article
16.

Inflammatory cytokines and survival factors from serum modulate tweak-induced apoptosis in PC-3 prostate cancer cells.

Sanz AB, Sanchez-Niño MD, Carrasco S, Manzarbeitia F, Ruiz-Andres O, Selgas R, Ruiz-Ortega M, Gonzalez-Enguita C, Egido J, Ortiz A.

PLoS One. 2012;7(10):e47440. doi: 10.1371/journal.pone.0047440. Epub 2012 Oct 15.

PMID:
23077618
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms.

Culp PA, Choi D, Zhang Y, Yin J, Seto P, Ybarra SE, Su M, Sho M, Steinle R, Wong MH, Evangelista F, Grove J, Cardenas M, James M, Hsi ED, Chao DT, Powers DB, Ramakrishnan V, Dubridge R.

Clin Cancer Res. 2010 Jan 15;16(2):497-508. doi: 10.1158/1078-0432.CCR-09-1929. Epub 2010 Jan 12.

PMID:
20068083
[PubMed - indexed for MEDLINE]
Free Article
18.

A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo.

Trebing J, Lang I, Chopra M, Salzmann S, Moshir M, Silence K, Riedel SS, Siegmund D, Beilhack A, Otto C, Wajant H.

MAbs. 2014 Jan-Feb;6(1):297-308.

PMID:
24135629
[PubMed - indexed for MEDLINE]
19.

Expression of TWEAK/Fn14 in neuroblastoma: implications in tumorigenesis.

Pettersen I, Baryawno N, Abel F, Bakkelund WH, Zykova SN, Winberg JO, Moens U, Rasmuson A, Kogner P, Johnsen JI, Sveinbjörnsson B.

Int J Oncol. 2013 Apr;42(4):1239-48. doi: 10.3892/ijo.2013.1800. Epub 2013 Jan 29.

PMID:
23443741
[PubMed - indexed for MEDLINE]
20.

Inhibition of TWEAK activity as a new treatment for inflammatory and degenerative diseases.

Yepes M, Winkles JA.

Drug News Perspect. 2006 Dec;19(10):589-95. Review.

PMID:
17299600
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk